Zacks: Analysts Expect Mirna Therapeutics, Inc. (SYBX) Will Post Earnings of -$0.78 Per Share
Brokerages forecast that Mirna Therapeutics, Inc. (NASDAQ:SYBX) will post ($0.78) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Mirna Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.79) and the highest estimate coming in at ($0.76). Mirna Therapeutics reported earnings of ($2.94) per share in the same quarter last year, which would indicate a positive year over year growth rate of 73.5%. The company is expected to issue its next earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Mirna Therapeutics will report full-year earnings of ($5.42) per share for the current year, with EPS estimates ranging from ($5.58) to ($5.26). For the next financial year, analysts expect that the firm will post earnings of ($2.76) per share, with EPS estimates ranging from ($3.35) to ($2.16). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Mirna Therapeutics.
SYBX has been the topic of several recent analyst reports. Wedbush started coverage on Mirna Therapeutics in a research report on Monday, November 27th. They set an “outperform” rating and a $20.00 target price on the stock. Zacks Investment Research cut Mirna Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 22nd. Leerink Swann initiated coverage on Mirna Therapeutics in a report on Tuesday, September 19th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, ValuEngine cut Mirna Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $19.67.
Mirna Therapeutics Company Profile
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.